论文部分内容阅读
目的观察沙利度胺联合PP方案对晚期肺腺癌患者疗效并研究其对血清TNF-α和VEGF水平的影响。方法选取2014-11-01-2015-11-01我院收治的晚期肺腺癌患者64例进行研究,并按照随机数表将其分成观察组32例和对照组32例。对照组患者进行培美曲塞和顺铂治疗方式(PP方案)进行治疗,观察组则在此基础上每日口服沙利度胺进行治疗。分别在治疗前和治疗后2个月检测患者的病理情况、体内血清中TNF-α和VEGF水平变化,统计两组患者的临床疗效、不良反应率以及患者疗后生活质量并作出相关的分析。结果治疗后,观察组和对照组血清中的TNF-α和VEGF水平均显著降低,P<0.05。且治疗后的观察组的TNF-α水平和VEGF水平明显低于对照组,P<0.05。观察组的总有效率明显高于对照组,差异有统计学意义,P<0.05。结论沙利度胺联合PP方案不仅能够显著降低患者血清中的TNF-α和VEGF水平,还能在治疗晚期肺腺癌中取得显著疗效。
Objective To observe the efficacy of thalidomide combined with PP regimen in patients with advanced lung adenocarcinoma and to study its effect on serum levels of TNF-α and VEGF. Methods Sixty-four patients with advanced lung adenocarcinoma admitted to our hospital from 2014-11-01-2015-11-01 were selected and divided into observation group (32 cases) and control group (32 cases) according to random number table. Patients in the control group were treated with pemetrexed and cisplatin (PP regimen), while those in the observation group were treated with oral thalidomide daily. The pathological changes, serum TNF-α and VEGF levels were measured before treatment and 2 months after treatment. The clinical efficacy, adverse reaction rate and quality of life after treatment were analyzed and analyzed. Results After treatment, the levels of TNF-α and VEGF in the serum of the observation group and the control group were significantly decreased (P <0.05). After treatment, the levels of TNF-α and VEGF in the observation group were significantly lower than those in the control group (P <0.05). The total effective rate of the observation group was significantly higher than that of the control group, the difference was statistically significant, P <0.05. Conclusions Thalidomide combined with PP regimen not only can significantly reduce the levels of TNF-α and VEGF in serum, but also achieve a significant effect in the treatment of advanced lung adenocarcinoma.